Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

The Patented Medicine Prices Review Board (PMPRB) published the 9th edition of its annual Meds Entry Watch report today. Like last year, the analysis finds that the number of new medicines launched in ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment options The multiple regulatory ...

A comprehensive analysis conducted by public health experts at Novartis Romania reveals that Romanian patients may wait, on ...

Introduction Over the past few years, the European Union has been actively working to overhaul its pharmaceutical legislative framework to better address unmet medical needs, such as those ...

A research team from the School of Clinical Medicine of the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) ...

The Patented Medicine Prices Review Board (PMPRB) published the 9th edition of its annual Meds Entry Watch report today. Like last year, the analysis ...

to the European Medicines Agency (EMA) for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome (SBS). The submission of the MAA to the EMA ...

The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.

The European Commission (EC) has granted marketing authorisation for Averoa's oral therapy Xoanacyl for chronic kidney ...